Study to Evaluate the Effect of Voxelotor in Participants 6 Months to 17 Years of Age With Sickle Cell Disease (HOPE-KIDS)
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Category & Conditions: Rare Diseases
Medicine: OXBRYTA(VOXELOTOR)
ClinicalTrials.gov Identifier (NCT): NCT02850406
Protocol ID: C5341020 (GBT440-007)
Open Plain Language Summary Result:
Click here